TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:44
PLIANT THERAPEUTICS INC. ( PLRX ) https://pliantrx.com
14.13USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-46.29%
PLRX
SPY
32.74%
-64.36%
PLRX
SPY
92.93%
PLRX
0.00%
SPY
224.41%
PLRX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
860.47
408.68
0.22
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.92
171.17
1.82
-12.41
0.00
-2.29
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-19227.82
100.00
-8579.48
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-683.72
-47.08
0.00
Other Earnings and Cash Flow Stats:
PLIANT THERAPEUTICS INC. ( PLRX ) Net Income TTM ($MM) is -132.19
PLIANT THERAPEUTICS INC. ( PLRX ) Operating Income TTM ($MM) is -159.13
PLIANT THERAPEUTICS INC. ( PLRX ) Owners' Earnings Annual ($MM) is -121.21
PLIANT THERAPEUTICS INC. ( PLRX ) Current Price to Owners' Earnings ratio is -6.99
PLIANT THERAPEUTICS INC. ( PLRX ) EBITDA TTM ($MM) is -147.60
PLIANT THERAPEUTICS INC. ( PLRX ) EBITDA Margin is -8579.48%
Capital Allocation:
PLIANT THERAPEUTICS INC. ( PLRX ) has paid 0.00 dividends per share and bought back -17.905094 million shares in the past 12 months
PLIANT THERAPEUTICS INC. ( PLRX ) has reduced its debt by 4.129 million USD in the last 12 months
Capital Structure:
PLIANT THERAPEUTICS INC. ( PLRX ) Interest-bearing Debt ($MM) as of last quarter is 14
PLIANT THERAPEUTICS INC. ( PLRX ) Annual Working Capital Investments ($MM) are -52
PLIANT THERAPEUTICS INC. ( PLRX ) Book Value ($MM) as of last quarter is 473
PLIANT THERAPEUTICS INC. ( PLRX ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
PLIANT THERAPEUTICS INC. ( PLRX ) has 63 million in cash on hand as of last quarter
PLIANT THERAPEUTICS INC. ( PLRX ) has 28 million of liabilities due within 12 months, and long term debt 10 as of last quarter
PLIANT THERAPEUTICS INC. ( PLRX ) has 59 common shares outstanding as of last quarter
PLIANT THERAPEUTICS INC. ( PLRX ) has 0 million USD of preferred stock value
Academic Scores:
PLIANT THERAPEUTICS INC. ( PLRX ) Altman Z-Score is 11.95 as of last quarter
PLIANT THERAPEUTICS INC. ( PLRX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
PLIANT THERAPEUTICS INC. ( PLRX ) largest shareholder is owning shares at 0.00 ($MM) value
Mike Ouimette(an insider) Sold 5197 shares of PLIANT THERAPEUTICS INC. ( PLRX ) for the amount of $89544.31 on 2024-01-17
5.85% of PLIANT THERAPEUTICS INC. ( PLRX ) is held by insiders, and 101.94% is held by institutions
PLIANT THERAPEUTICS INC. ( PLRX ) went public on 2020-06-03
Other PLIANT THERAPEUTICS INC. ( PLRX ) financial metrics:
FCF:-117.36
Unlevered Free Cash Flow:-79.66
EPS:-2.77
Operating Margin:-19227.82
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-35.04
Beta:0.00
Buffet's Owners Earnings:-121.21
Price to Owner's Earnings:-6.99
About PLIANT THERAPEUTICS INC. ( PLRX ) :
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.